According to CNN, the shares of leading vaccine manufacturers plummeted on Thursday after President-elect Donald Trump ...

Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, approximately $5B and $5.5B, respectively. Including the contribution ...